{"doc_id": "33422263", "type of study": "Therapy", "title": "", "abstract": "Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.\nBiological considerations suggest that renin-angiotensin system inhibitors might influence the severity of COVID-19.\nWe aimed to evaluate whether continuing versus discontinuing renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) affects outcomes in patients admitted to hospital with COVID-19.\nThe REPLACE COVID trial was a prospective, randomised, open-label trial done at 20 large referral hospitals in seven countries worldwide.\nEligible participants were aged 18 years and older who were admitted to hospital with COVID-19 and were receiving a renin-angiotensin system inhibitor before admission.\nIndividuals with contraindications to continuation or discontinuation of renin-angiotensin system inhibitor therapy were excluded.\nParticipants were randomly assigned (1:1) to continuation or discontinuation of their renin-angiotensin system inhibitor using permuted block randomisation, with allocation concealed using a secure web-based randomisation system.\nThe primary outcome was a global rank score in which participants were ranked across four hierarchical tiers incorporating time to death, duration of mechanical ventilation, time on renal replacement or vasopressor therapy, and multiorgan dysfunction during the hospitalisation.\nPrimary analyses were done in the intention-to-treat population.\nThe REPLACE COVID trial is registered with ClinicalTrials.gov, NCT04338009.\nBetween March 31 and Aug 20, 2020, 152 participants were enrolled and randomly assigned to either continue or discontinue renin-angiotensin system inhibitor therapy (continuation group n=75; discontinuation group n=77).\nMean age of participants was 62 years (SD 12), 68 (45%) were female, mean body-mass index was 33 kg/m2 (SD 8), and 79 (52%) had diabetes.\nCompared with discontinuation of renin-angiotensin system inhibitors, continuation had no effect on the global rank score (median rank 73 [IQR 40-110] for continuation vs 81 [38-117] for discontinuation; \u03b2-coefficient 8 [95% CI -13 to 29]).\nThere were 16 (21%) of 75 participants in the continuation arm versus 14 (18%) of 77 in the discontinuation arm who required intensive care unit admission or invasive mechanical ventilation, and 11 (15%) of 75 participants in the continuation group versus ten (13%) of 77 in the discontinuation group died.\n29 (39%) participants in the continuation group and 28 (36%) participants in the discontinuation group had at least one adverse event (\u03c72 test of adverse events between treatment groups p=0\u00b777).\nThere was no difference in blood pressure, serum potassium, or creatinine during follow-up across the two groups.\nConsistent with international society recommendations, renin-angiotensin system inhibitors can be safely continued in patients admitted to hospital with COVID-19.\nREPLACE COVID Investigators, REPLACE COVID Trial Social Fundraising Campaign, and FastGrants.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 107}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 113, "end": 121}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 204, "end": 224}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 80}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 94}, {"term": "renin-angiotensin system inhibitor", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 150}, {"term": "contraindications to continuation or discontinuation of renin-angiotensin system inhibitor therapy", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 115}, {"term": "admitted", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 136}, {"term": "hospital", "negation": "affirmed", "UMLS": {}, "start": 140, "end": 148}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19 : a prospective , randomised , open-label trial .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 107}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 113, "end": 121}], "Intervention": [{"term": "Continuation", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 12}, {"term": "discontinuation of renin-angiotensin system inhibitors", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 74}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Biological considerations suggest that renin-angiotensin system inhibitors might influence the severity of COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We aimed to evaluate whether continuing versus discontinuing renin-angiotensin system inhibitors ( angiotensin-converting enzyme inhibitors or angiotensin receptor blockers ) affects outcomes in patients admitted to hospital with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 204, "end": 224}], "Intervention": [{"term": "continuing versus discontinuing renin-angiotensin system inhibitors", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 96}, {"term": "enzyme inhibitors or", "negation": "affirmed", "UMLS": {}, "start": 122, "end": 142}, {"term": "receptor blockers", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 172}], "Outcome": [{"term": "outcomes", "negation": "affirmed", "UMLS": {}, "start": 183, "end": 191}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The REPLACE COVID trial was a prospective , randomised , open-label trial done at 20 large referral hospitals in seven countries worldwide .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Eligible participants were aged 18 years and older who were admitted to hospital with COVID-19 and were receiving a renin-angiotensin system inhibitor before admission .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 80}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 94}, {"term": "renin-angiotensin system inhibitor", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 150}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Individuals with contraindications to continuation or discontinuation of renin-angiotensin system inhibitor therapy were excluded .", "Evidence Elements": {"Participant": [{"term": "contraindications to continuation or discontinuation of renin-angiotensin system inhibitor therapy", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 115}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Participants were randomly assigned (1:1) to continuation or discontinuation of their renin-angiotensin system inhibitor using permuted block randomisation , with allocation concealed using a secure web-based randomisation system .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "continuation", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 57}, {"term": "discontinuation of their renin-angiotensin system inhibitor", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 120}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was a global rank score in which participants were ranked across four hierarchical tiers incorporating time to death , duration of mechanical ventilation , time on renal replacement or vasopressor therapy , and multiorgan dysfunction during the hospitalisation .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "global rank score", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 43}, {"term": "time to death", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 136}, {"term": "duration of mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 173}, {"term": "time on renal replacement or vasopressor therapy", "negation": "affirmed", "UMLS": {}, "start": 176, "end": 224}, {"term": "multiorgan dysfunction", "negation": "affirmed", "UMLS": {}, "start": 231, "end": 253}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Primary analyses were done in the intention-to-treat population .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The REPLACE COVID trial is registered with ClinicalTrials.gov , NCT04338009 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Between March 31 and Aug 20, 2020 , 152 participants were enrolled and randomly assigned to either continue or discontinue renin-angiotensin system inhibitor therapy ( continuation group n = 75 ; discontinuation group n = 77 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "continue", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 107}, {"term": "discontinue renin-angiotensin system inhibitor therapy", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 165}, {"term": "continuation", "negation": "affirmed", "UMLS": {}, "start": 168, "end": 180}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Mean age of participants was 62 years ( SD 12 ) , 68 ( 45 % ) were female , mean body-mass index was 33 kg / m2 ( SD 8 ) , and 79 ( 52 % ) had diabetes .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Compared with discontinuation of renin-angiotensin system inhibitors , continuation had no effect on the global rank score ( median rank 73 [ IQR 40-110 ] for continuation vs 81 [ 38-117 ] for discontinuation ; \u03b2-coefficient 8 [ 95 % CI-13 to 29 ] ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "discontinuation of renin-angiotensin system inhibitors", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 68}, {"term": "continuation", "negation": "negated", "UMLS": {}, "start": 17, "end": 29}, {"term": "continuation", "negation": "negated", "UMLS": {}, "start": 17, "end": 29}, {"term": "discontinuation", "negation": "negated", "UMLS": {}, "start": 14, "end": 29}], "Outcome": [{"term": "global rank score", "negation": "negated", "UMLS": {}, "start": 105, "end": 122}], "Observation": [{"term": "effect", "negation": "negated", "UMLS": {}, "start": 91, "end": 97}], "Count": []}, "Evidence Propositions": [{"Intervention": "continuation", "Observation": "effect", "Outcome": "global rank score", "Count": ""}]}, {"Section": "FINDINGS", "Text": "There were 16 ( 21 % ) of 75 participants in the continuation arm versus 14 ( 18 % ) of 77 in the discontinuation arm who required intensive care unit admission or invasive mechanical ventilation , and 11 ( 15 % ) of 75 participants in the continuation group versus ten ( 13 % ) of 77 in the discontinuation group died .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "continuation", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 61}, {"term": "discontinuation", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 113}, {"term": "continuation", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 61}], "Outcome": [{"term": "intensive care unit admission", "negation": "affirmed", "UMLS": {}, "start": 131, "end": 160}, {"term": "invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 164, "end": 195}], "Observation": [], "Count": [{"term": "16 ( 21 % ) of 75 participants", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 41}, {"term": "14 ( 18 % ) of 77", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 90}, {"term": "11 ( 15 % ) of 75 participants", "negation": "affirmed", "UMLS": {}, "start": 202, "end": 232}]}, "Evidence Propositions": [{"Intervention": "continuation", "Observation": "", "Count": "16 ( 21 % ) of 75 participants", "Outcome": "intensive care unit admission"}, {"Intervention": "discontinuation", "Observation": "", "Count": "14 ( 18 % ) of 77", "Outcome": "intensive care unit admission"}]}, {"Section": "FINDINGS", "Text": "29 ( 39 % ) participants in the continuation group and 28 ( 36 % ) participants in the discontinuation group had at least one adverse event ( \u03c72 test of adverse events between treatment groups p = 0\u00b777 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "continuation", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 44}, {"term": "discontinuation", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 102}], "Outcome": [{"term": "least one adverse event", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 139}], "Observation": [], "Count": [{"term": "29 ( 39 % ) participants", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 24}, {"term": "28 ( 36 % ) participants", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 79}]}, "Evidence Propositions": [{"Intervention": "continuation", "Observation": "", "Count": "29 ( 39 % ) participants", "Outcome": "least one adverse event"}, {"Intervention": "discontinuation", "Observation": "", "Count": "28 ( 36 % ) participants", "Outcome": "least one adverse event"}]}, {"Section": "FINDINGS", "Text": "There was no difference in blood pressure , serum potassium , or creatinine during follow-up across the two groups .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "blood pressure", "negation": "negated", "UMLS": {}, "start": 27, "end": 41}, {"term": "serum potassium", "negation": "negated", "UMLS": {}, "start": 44, "end": 59}, {"term": "creatinine", "negation": "negated", "UMLS": {}, "start": 65, "end": 75}], "Observation": [{"term": "difference", "negation": "negated", "UMLS": {}, "start": 13, "end": 23}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "difference", "Outcome": "blood pressure", "Count": ""}, {"Intervention": [], "Observation": "difference", "Outcome": "serum potassium", "Count": ""}, {"Intervention": [], "Observation": "difference", "Outcome": "creatinine", "Count": ""}]}, {"Section": "INTERPRETATION", "Text": "Consistent with international society recommendations , renin-angiotensin system inhibitors can be safely continued in patients admitted to hospital with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "admitted", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 136}, {"term": "hospital", "negation": "affirmed", "UMLS": {}, "start": 140, "end": 148}], "Intervention": [], "Outcome": [], "Observation": [{"term": "safely continued", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 115}], "Count": []}, "Evidence Propositions": []}, {"Section": "FUNDING", "Text": "REPLACE COVID Investigators , REPLACE COVID Trial Social Fundraising Campaign , and FastGrants .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}